Gadoversetamide

Drug Profile

Gadoversetamide

Alternative Names: Gd-DTPA-BMEA; MP 1177; OptiMARK

Latest Information Update: 06 May 2017

Price : $50

At a glance

  • Originator Mallinckrodt Medical
  • Class Contrast media; Organometallic compounds; Small molecules
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed CNS disorders; Liver disorders
  • No development reported Myocardial infarction

Most Recent Events

  • 10 Mar 2017 EMA's Pharmacovigilance Risk Assessment Committee recommends suspension of gadoversetamide from the market in the European Union
  • 03 Jan 2017 Launched for Liver disorders and CNS disorders (Diagnosis) in Ireland (IV) (before January 2017)
  • 10 Nov 2016 Launched for Liver disorders and CNS disorders (Diagnosis) in Poland (IV) (before November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top